{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:57:32Z","timestamp":1781333852038,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004918","name":"Council on Competitive Government","doi-asserted-by":"publisher","award":["1R01HL157027"],"award-info":[{"award-number":["1R01HL157027"]}],"id":[{"id":"10.13039\/100004918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004918","name":"Council on Competitive Government","doi-asserted-by":"publisher","award":["1R01HL174545"],"award-info":[{"award-number":["1R01HL174545"]}],"id":[{"id":"10.13039\/100004918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004918","name":"Council on Competitive Government","doi-asserted-by":"publisher","award":["1R01HL180520"],"award-info":[{"award-number":["1R01HL180520"]}],"id":[{"id":"10.13039\/100004918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004918","name":"Council on Competitive Government","doi-asserted-by":"publisher","award":["1R01HL174576"],"award-info":[{"award-number":["1R01HL174576"]}],"id":[{"id":"10.13039\/100004918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004918","name":"Council on Competitive Government","doi-asserted-by":"publisher","award":["1R56HL174545"],"award-info":[{"award-number":["1R56HL174545"]}],"id":[{"id":"10.13039\/100004918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["1R01HL174576"],"award-info":[{"award-number":["1R01HL174576"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["1R56HL174545"],"award-info":[{"award-number":["1R56HL174545"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["1R01HL157027"],"award-info":[{"award-number":["1R01HL157027"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["1F31HL172675"],"award-info":[{"award-number":["1F31HL172675"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["T32HL007249"],"award-info":[{"award-number":["T32HL007249"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017995","name":"Nora Eccles Treadwell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology Plus"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jmccpl.2026.100846","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:30:47Z","timestamp":1776187847000},"page":"100846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Doxorubicin exposure leads to cardiac fibroblast dysregulation and worsens fibrotic remodeling in the pathological heart"],"prefix":"10.1016","volume":"16","author":[{"given":"Sukriti","family":"Bagchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina S.","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gamez-Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rosa-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinalini","family":"Kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Glembotski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Blackwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jmccpl.2026.100846_bb0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100846_bb0010","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-lnduced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jmccpl.2026.100846_bb0015","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jmccpl.2026.100846_bb0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.hfc.2011.03.001","article-title":"A historical perspective of anthracycline cardiotoxicity","volume":"7","author":"Ewer","year":"2011","journal-title":"Heart Fail Clin"},{"issue":"9","key":"10.1016\/j.jmccpl.2026.100846_bb0025","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"2016","author":"Van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.jmccpl.2026.100846_bb0030","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.jmccpl.2026.100846_bb0035","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer","volume":"41","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jmccpl.2026.100846_bb0040","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med"},{"issue":"dec08 1","key":"10.1016\/j.jmccpl.2026.100846_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jmccpl.2026.100846_bb0050","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/j.2040-4603.2019.tb00082.x","article-title":"Doxorubicin-induced cardiomyopathy in children","volume":"9","author":"Mancilla","year":"2019","journal-title":"Compr Physiol"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100846_bb0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486761","article-title":"Early diastolic dysfunction after cancer chemotherapy: primary endpoint results of a multicenter cardio-oncology study","volume":"63","author":"Calabrese","year":"2018","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaccao.2021.12.002","article-title":"From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach","volume":"4","author":"Minotti","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jmccpl.2026.100846_bb0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pcad.2024.07.002","article-title":"Anthracyclines, diastolic dysfunction and the road to heart failure in cancer survivors: an untold story","volume":"86","author":"Camilli","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"25","key":"10.1016\/j.jmccpl.2026.100846_bb0070","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr Med Chem"},{"issue":"11","key":"10.1016\/j.jmccpl.2026.100846_bb0075","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0080","article-title":"Doxorubicin cardiotoxicity and target cells: a broader perspective","volume":"2","author":"De Angelis","year":"2016","journal-title":"Cardio-Oncol"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41514-024-00135-7","article-title":"A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging","volume":"10","author":"Linders","year":"2024","journal-title":"NPJ Aging"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0095","first-page":"27","article-title":"Pharmacokinetics and metabolism of anthracyclines in man","volume":"35","author":"Robert","year":"1987","journal-title":"Pathol Biol (Paris)"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00685876","article-title":"Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit","volume":"32","author":"Cusack","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.jmccpl.2026.100846_bb0105","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-018-2456-8","article-title":"A multiscale physiologically-based pharmacokinetic model for doxorubicin to explore its mechanisms of cytotoxicity and cardiotoxicity in human physiological contexts","volume":"35","author":"He","year":"2018","journal-title":"Pharm Res"},{"issue":"4\u20135","key":"10.1016\/j.jmccpl.2026.100846_bb0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bdd.2229","article-title":"Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling","volume":"41","author":"Lee","year":"2020","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100846_bb0115","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amjcard.2012.11.022","article-title":"Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy","volume":"111","author":"Neilan","year":"2013","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.jmccpl.2026.100846_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.004325","article-title":"Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors","volume":"9","author":"Jordan","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jmccpl.2026.100846_bb0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijcard.2015.12.008","article-title":"SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy","volume":"205","author":"Cappetta","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100846_bb0130","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ehf2.12616","article-title":"Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"10","key":"10.1016\/j.jmccpl.2026.100846_bb0135","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.hlc.2018.08.003","article-title":"Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts","volume":"28","author":"Levick","year":"2019","journal-title":"Heart Lung Circ"},{"issue":"6","key":"10.1016\/j.jmccpl.2026.100846_bb0140","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10.1016\/j.jmccpl.2026.100846_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071716","article-title":"Cardiac Fibrosis and Fibroblasts","volume":"10","author":"Kurose","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jmccpl.2026.100846_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.670479","article-title":"Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician","volume":"12","author":"Podyacheva","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jmccpl.2026.100846_bb0155","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69854","article-title":"Consequences of PDGFR\u03b1+ fibroblast reduction in adult murine hearts","volume":"11","author":"Kuwabara","year":"2022","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/CIRCULATIONAHA.122.061557","article-title":"Noncanonical form of ERAD regulates cardiac hypertrophy","volume":"147","author":"Blackwood","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jmccpl.2026.100846_bb0165","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/CIRCRESAHA.119.316162","article-title":"Infarct collagen topography regulates fibroblast fate via p38-Yes-Associated protein transcriptional enhanced associate domain signals","volume":"127","author":"Bugg","year":"2020","journal-title":"Circ Res"},{"issue":"23","key":"10.1016\/j.jmccpl.2026.100846_bb0170","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/CIRCULATIONAHA.123.066860","article-title":"MBNL1 regulates programmed postnatal switching between regenerative and differentiated cardiac states","volume":"149","author":"LRJ","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100846_bb0175","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1074\/jbc.RA117.000444","article-title":"Glutaminolysis is required for transforming growth factor-\u03b21-induced myofibroblast differentiation and activation","volume":"293","author":"Bernard","year":"2018","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12103-x","article-title":"Mitochondrial calcium exchange links metabolism with the epigenome to control cellular differentiation","volume":"10","author":"Lombardi","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100846_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166642","article-title":"Senescent cardiac fibroblasts: a key role in cardiac fibrosis","volume":"1869","author":"Osorio","year":"2023","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"issue":"12","key":"10.1016\/j.jmccpl.2026.100846_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26125882","article-title":"The role of cardiac fibroblast heterogeneity in myocardial fibrosis and its novel therapeutic potential","volume":"26","author":"Chimenti","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100846_bb0195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.jmccpl.2026.100846_bb0200","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-022-04400-y","article-title":"Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells","volume":"89","author":"Nicoletto","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7838","key":"10.1016\/j.jmccpl.2026.100846_bb0205","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41586-020-2797-4","article-title":"Cells of the adult human heart","volume":"588","author":"Litvi\u0148ukov\u00e1","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jmccpl.2026.100846_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221940","article-title":"Doxorubicin induces trans-differentiation and MMP1 expression in cardiac fibroblasts via cell death-independent pathways","volume":"14","author":"Narikawa","year":"2019","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.jmccpl.2026.100846_bb0215","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","article-title":"ERK signalling: a master regulator of cell behaviour, life and fate","volume":"21","author":"Lavoie","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.jmccpl.2026.100846_bb0220","first-page":"704","article-title":"Epigenetics in cardiac fibrosis","volume":"3","author":"Felisbino","year":"2018","journal-title":"JACC: Basic Transl Sci"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100846_bb0225","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s44161-024-00460-w","article-title":"Histone H1.0 couples cellular mechanical behaviors to chromatin structure","volume":"3","author":"Hu","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jmccpl.2026.100846_bb0230","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.phrs.2017.03.016","article-title":"Doxorubicin targets multiple players: a new view of an old problem","volume":"127","author":"Cappetta","year":"2018","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.jmccpl.2026.100846_bb0235","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.124.004813","article-title":"DNA damage response and repair genes and anthracycline-induced cardiomyopathy in childhood cancer survivors: a report from the Children\u2019s Oncology Group and the Childhood Cancer Survivor Study","volume":"18","author":"Wang","year":"2025","journal-title":"Circ Genom Precis Med"},{"issue":"12","key":"10.1016\/j.jmccpl.2026.100846_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2024.10.007","article-title":"CRISPRi\/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity","volume":"31","author":"Liu","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41540-025-00545-7","article-title":"Temporal analysis of doxorubicin-induced cardiac toxicity and hypertrophy","volume":"11","author":"Lin","year":"2025","journal-title":"NPJ Syst Biol Appl"},{"issue":"1","key":"10.1016\/j.jmccpl.2026.100846_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-06385-8","article-title":"Cardiac spheroids as promising in vitro models to study the human heart microenvironment","volume":"7","author":"Polonchuk","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jmccpl.2026.100846_bb0255","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41551-020-0539-4","article-title":"Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity","volume":"4","author":"Richards","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jmccpl.2026.100846_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110777","article-title":"Assessment of doxorubicin toxicity using human cardiac organoids: a novel model for evaluating drug cardiotoxicity","volume":"386","author":"Chen","year":"2023","journal-title":"Chem Biol Interact"}],"container-title":["Journal of Molecular and Cellular Cardiology Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772976126000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772976126000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:52:49Z","timestamp":1781333569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772976126000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"alternative-id":["S2772976126000139"],"URL":"https:\/\/doi.org\/10.1016\/j.jmccpl.2026.100846","relation":{},"ISSN":["2772-9761"],"issn-type":[{"value":"2772-9761","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doxorubicin exposure leads to cardiac fibroblast dysregulation and worsens fibrotic remodeling in the pathological heart","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmccpl.2026.100846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100846"}}